{"id":"https://openalex.org/W2249124379","doi":null,"title":"Antagonist properties of d-LSD at 5-hydroxytryptamine2 receptors.","display_name":"Antagonist properties of d-LSD at 5-hydroxytryptamine2 receptors.","publication_year":1990,"publication_date":"1990-10-01","ids":{"openalex":"https://openalex.org/W2249124379","mag":"2249124379","pmid":"https://pubmed.ncbi.nlm.nih.gov/2078283"},"language":"en","primary_location":{"id":"pmid:2078283","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2078283","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109171010","display_name":"Pamela A. Pierce","orcid":"https://orcid.org/0000-0002-0384-7624","observed_orcids":["https://orcid.org/0000-0002-0384-7624"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P A Pierce","raw_affiliation_strings":["Department of Neurology, Stanford University Medical Center, CA 94305"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, Stanford University Medical Center, CA 94305","institution_ids":["https://openalex.org/I4210137306"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080962550","display_name":"Stephen J. Peroutka","orcid":"https://orcid.org/0000-0003-3333-4819","observed_orcids":["https://orcid.org/0000-0003-3333-4819"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S J Peroutka","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.2809,"has_fulltext":false,"cited_by_count":27,"citation_normalized_percentile":{"value":0.92108591,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"3","issue":"5-6","first_page":"503","last_page":"8"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12553","display_name":"Psychedelics and Drug Studies","score":0.9672999978065491,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T12553","display_name":"Psychedelics and Drug Studies","score":0.9672999978065491,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.026799999177455902,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lsd","display_name":"LSD","score":0.8510000109672546},{"id":"https://openalex.org/keywords/5-ht2-receptor","display_name":"5-HT2 receptor","score":0.8349999785423279},{"id":"https://openalex.org/keywords/serotonin-receptors","display_name":"serotonin receptors","score":0.6650000214576721},{"id":"https://openalex.org/keywords/5-ht1a-receptor","display_name":"5-HT1A receptor","score":0.800000011920929},{"id":"https://openalex.org/keywords/5-ht2c-receptor","display_name":"5-HT2C receptor","score":0.9990000128746033},{"id":"https://openalex.org/keywords/receptor-antagonism","display_name":"receptor antagonism","score":0.8130000233650208},{"id":"https://openalex.org/keywords/receptor-agonism","display_name":"receptor agonism","score":0.9539999961853027},{"id":"https://openalex.org/keywords/hallucinosis","display_name":"hallucinosis","score":0.9229999780654907}],"concepts":[{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.7975002527236938},{"id":"https://openalex.org/C124315065","wikidata":"https://www.wikidata.org/wiki/Q194270","display_name":"Hallucinogen","level":2,"score":0.793715238571167},{"id":"https://openalex.org/C2779871769","wikidata":"https://www.wikidata.org/wiki/Q23118","display_name":"Lysergic acid diethylamide","level":4,"score":0.7015775442123413},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.6862205266952515},{"id":"https://openalex.org/C200220013","wikidata":"https://www.wikidata.org/wiki/Q753586","display_name":"5-HT2 receptor","level":5,"score":0.6289325952529907},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.5914806127548218},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5627982020378113},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.5376732349395752},{"id":"https://openalex.org/C160262196","wikidata":"https://www.wikidata.org/wiki/Q5376331","display_name":"Endogenous agonist","level":5,"score":0.5361648797988892},{"id":"https://openalex.org/C53910766","wikidata":"https://www.wikidata.org/wiki/Q238516","display_name":"5-HT receptor","level":4,"score":0.5253543257713318},{"id":"https://openalex.org/C2776120743","wikidata":"https://www.wikidata.org/wiki/Q3271540","display_name":"Mechanism of action","level":3,"score":0.4734342098236084},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.4715597331523895},{"id":"https://openalex.org/C172773627","wikidata":"https://www.wikidata.org/wiki/Q753583","display_name":"5-HT1 receptor","level":5,"score":0.4536941349506378},{"id":"https://openalex.org/C2778539182","wikidata":"https://www.wikidata.org/wiki/Q4693408","display_name":"Agonist-antagonist","level":4,"score":0.4265499711036682},{"id":"https://openalex.org/C2778122271","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Receptor antagonist","level":4,"score":0.4107004404067993},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.41026657819747925},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.18306559324264526},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12163752317428589},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.06386786699295044},{"id":"https://openalex.org/C120750228","wikidata":"https://www.wikidata.org/wiki/Q2035393","display_name":"Dopamine receptor D1","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008238","descriptor_name":"Lysergic Acid Diethylamide","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011985","descriptor_name":"Receptors, Serotonin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D012702","descriptor_name":"Serotonin Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:2078283","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2078283","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","raw_type":"Journal Article"},{"id":"mag:2249124379","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2078283","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8048999905586243}],"study_designs":[],"awards":[{"id":"https://openalex.org/G8814616288","display_name":"CHARACTERIZATION OF SEROTONIN RECEPTOR SUBTYES","funder_award_id":"R01NS023560","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"}],"funders":[{"id":"https://openalex.org/F4320337359","display_name":"National Institute of Neurological Disorders and Stroke","ror":"https://ror.org/01s5ya894"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1995108501","https://openalex.org/W2970511278","https://openalex.org/W2141244106","https://openalex.org/W2014849557","https://openalex.org/W2316059351","https://openalex.org/W1979905339","https://openalex.org/W2038393570","https://openalex.org/W1980453588","https://openalex.org/W1980348146","https://openalex.org/W2063194215"],"abstract_inverted_index":{"The":[0],"hallucinogenic":[1,108],"agent":[2],"d-lysergic":[3],"acid":[4],"diethylamide":[5],"(d-LSD)":[6],"interacts":[7],"with":[8],"a":[9,55,100],"number":[10],"of":[11,105,107],"serotonin":[12],"(5-hydroxytryptamine":[13],"[5-HT])":[14],"receptor":[15,76],"subtypes":[16],"in":[17,63,80],"the":[18,84],"central":[19],"nervous":[20],"system.":[21],"It":[22],"has":[23],"been":[24],"hypothesized":[25],"that":[26,50,52],"hallucinosis":[27],"is":[28,54],"produced":[29],"by":[30],"agonist":[31,70,87],"activity":[32,71],"at":[33,72,89],"5-HT2":[34,57,95],"receptors.":[35],"There":[36],"exist,":[37],"however,":[38],"numerous":[39],"data":[40,60],"from":[41],"radioligand":[42],"binding,":[43],"cellular,":[44],"smooth":[45],"muscle,":[46],"and":[47,74],"behavioral":[48],"studies":[49],"suggest":[51],"d-LSD":[53,68],"potent":[56],"antagonist.":[58],"These":[59],"are":[61],"reviewed":[62],"this":[64],"report.":[65],"In":[66],"addition,":[67],"displays":[69],"5-HT1A":[73],"5-HT1C":[75,90],"subtypes,":[77],"as":[78,92],"determined":[79],"biochemical":[81],"studies.":[82],"At":[83],"present":[85],"time,":[86],"interactions":[88],"receptors,":[91,96],"opposed":[93],"to":[94,98],"appears":[97],"be":[99],"more":[101],"likely":[102],"\"common":[103],"mechanism":[104],"action\"":[106],"agents.":[109]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2016-06-24T00:00:00"}